EZH2 and breast carcinoma: Aberrant PRC2 activity, sometimes caused by EZH2 mutations, is frequently associated with poor prognosis in hematological, lung, prostate, and breast cancer [62], and several small molecule inhibitors of EZH2 have recently been developed, including some currently evaluated in clinical trials.